201 Industrial Road
LakePharma is a US-based Biologics CRDMO with operations in CA, MA, and TX that provides integrated solutions ranging from discovery to engineering, development, and GMP manufacturing. The company specializes in the production and evaluation of antibodies, DNA vectors, viral vectors, cell lines, proteins, and conjugates. LakePharma has contributed to the development of 200+ therapeutic or diagnostic products and strives to contribute to hundreds more. LakePharma is ISO 9001:2015 and ISO 13485:2016 certified.
27 articles with LakePharma
LakePharma announces that the company will be supplying the Mount Sinai Health System recombinant SARS-CoV-2 spike proteins to the Mount Sinai Laboratory as a component in its blood test for antibody response against SARS-CoV-2, the virus that causes the COVID-19 pandemic.
LakePharma and NJ Bio Form Strategic Alliance to Provide Streamlined Antibody-Drug Conjugate Services
LakePharma, Inc., the leading US-based biologics CRDMO, and NJ Biopharmaceuticals LLC (d/b/a NJ Bio), a CRO providing integrated chemistry and biology services, today announce the formation of a strategic alliance to offer streamlined antibody-drug conjugate (ADC) development solutions for the biotech
Distinguished Speakers to Present Latest Developments in Next-Generation Therapeutics
The new location allows LakePharma to better align its services with clients' demands in the rapidly growing biologics industry.
LakePharma, Inc., the leading US-based biologics CRDMO, announced the launch of GMP manufacturing of recombinant proteins and antibodies with CHO-GSN™ and TunaCHO™ platforms at its Hayward, California facility.
The center is located in Worcester, MA, which is in close proximity to the Cambridge and Boston areas.
LakePharma Announces its GMP Biorepository Facility near Boston is Now Operational, Plans Additional Hiring
LakePharma, Inc. announced that their GMP biorepository facility is now commercially operational at their Hopkinton, MA location, which is in close proximity to the Cambridge and Boston areas.
LakePharma, Inc., the leading US-based biologics company specializing in antibody & protein engineering, cell line development, and protein production, announced today that their cGMP microBiomanufacturing™ Center is now commercially manufacturing plasmid DNA at their Hopkinton, MA location, which is in close proximity to the Cambridge and Boston areas.
LakePharma, the leading US-based biologics company specializing in antibody and protein engineering, cell line development, and protein production, announced today that it has successfully completed moving and consolidating all of its antibody services at its new location at 201 Industrial Rd., San Carlos, CA.
LakePharma Announces "New Frontiers in Biologics" as The Theme for Its Annual Protein Engineering Symposium in 2018
The Bay Area Annual Event Will Be Held on October 5th at the South San Francisco Conference Center
In March venture capital firm ShangPharma Innovations announced its plans to expand its life sciences incubator in San Francisco by 40 percent, including state-of-the-art laboratory infrastructure upgrades to its facility. That investment is paying off as the incubator is growing.
LakePharma and Harbour Antibodies Announce Partnership for H2L2 Transgenic Mouse Platform for Therapeutic Antibody Discovery
Agreement Provides for Easy Access to H2L2 Platform Use with LakePharma's Discovery and Development Services
After a two-year wait, AstraZeneca finally has employees under one roof in the Bay Area.
The funding will be used to enhance LakePharma's existing service offering and grow the company's biomanufacturing capabilities.
The relationship between Hemogenyx Pharmaceuticals and LakePharma is designed to have a seamless product development process, from discovery to biomanufacturing
Want to work for a company having a growth spurt?